Duplications and Defects in theCYP2A6Gene: Identification, Genotyping, and In Vivo Effects on Smoking
- 1 October 2000
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 58 (4) , 747-755
Abstract
In humans, 80% of nicotine is metabolized to the inactive metabolite cotinine by the enzyme CYP2A6, which can also activate tobacco smoke procarcinogens (e.g., 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone). Previously, we demonstrated that individuals who are nicotine-dependent and have defective CYP2A6 alleles (*2, *3) smoked fewer cigarettes; however, we recognize that the genotyping method used for the CYP2A6*3 allele gave a high false-positive rate. In the current study we used improved genotyping methods to examine the effects of the defectiveCYP2A6*2 and CYP2A6*4 alleles on smoking behavior. We found that those with the defective alleles (N = 14) smoked fewer cigarettes per day than those homozygous (N = 277) for wild-type alleles (19 versus 28 cigarettes per day, P < .001). In addition, we identified a duplicated form of the CYP2A6gene, corresponding to the gene deletion CYP2A6*4allele, developed a genotyping assay, assessed the gene copy number, and examined its prevalence in Caucasian smokers (N= 296). We observed an ascending rank order for plasma cotinine and breath carbon monoxide levels (an index of smoke inhalation) in individuals with null (CYP2A6*2 andCYP2A6*4) alleles (N = 14), those homozygous for wild-type (CYP2A6*1/*1) alleles (N = 277), and those with our newly identifiedCYP2A6 gene duplication (N = 5). The phenotype, as determined by plasma nicotine/cotinine ratios, had a descending rank order for these three genotype groups that did not reach significance. Although further characterization is required for the duplication gene variant, these results extend our previous findings and suggest a substantial influence of CYP2A6genotype and phenotype on smoking behavior.Keywords
This publication has 25 references indexed in Scilit:
- Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humansClinical Pharmacology & Therapeutics, 2000
- Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolismFEBS Letters, 1999
- CYP2A6 Gene Deletion Reduces Susceptibility to Lung CancerBiochemical and Biophysical Research Communications, 1999
- Homologous Unequal Cross-Over within the Human CYP2A Gene Cluster as a Mechanism for the Deletion of the Entire CYP2A6 Gene Associated with the Poor Metabolizer PhenotypeThe Journal of Biochemistry, 1999
- Characterization of Multiple Products of Cytochrome P450 2A6-Catalyzed Cotinine MetabolismChemical Research in Toxicology, 1999
- Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction methodPharmacogenetics, 1999
- Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C‐oxidaseFEBS Letters, 1998
- A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3 -pyridyl)thiazolidin-4-one hydrochloride (SM-12502)Pharmacogenetics, 1998
- Human cytochrome P450IIA3: cDNA sequence role of the enzyme in the metabolic of promutagens comparison to nitrosamine activation by human cytochrome P450IIE1Carcinogenesis, 1990
- Nicotine's role in smoking: An analysis of nicotine regulation.Psychological Bulletin, 1983